3-(1-amino-2-methyl-1-oxopropan-2-yl)benzoic acid | 1191944-16-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(1-amino-2-methyl-1-oxopropan-2-yl)benzoic acid
• CAS: 1191944-16-7
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: KAIZLAZLACSFBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(1-氰基-1-甲基乙基)苯甲酸 在 lithium hydroxide monohydrate 、 双氧水 、 盐酸 、 水 作用下， 以 乙醇 、 水 为溶剂， 反应 18.0h， 以48%的产率得到3-(1-amino-2-methyl-1-oxopropan-2-yl)benzoic acid
  参考文献：
  名称：

  CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS

  摘要：

  揭示了在改善以不需要的钙通道活性为特征的情况下有效的方法和化合物，特别是不需要的N型和/或T型钙通道活性。具体而言，公开了一系列经取代或未取代的环胺衍生物的化合物，如公式（1）所示。

  公开号：

  US20090270394A1

文献信息

• Amino acid derivatives as calcium channel blockers
  申请人：Galemmo, JR. Robert

  公开号：US20090012010A1

  公开（公告）日：2009-01-08

  Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds containing both an amino acid functionality and multiple aromatic rings are disclosed of the general formula (1) where X is benzhydryl, or an aromatic or heteroaromatic ring.

  本发明揭示了一种对具有不需要的钙通道活性，特别是不需要的N型和/或T型钙通道活性所表征的疾病状况具有改善作用的方法和化合物。具体而言，本发明揭示了一系列化合物，其含有氨基酸功能和多个芳香环，其一般式为（1），其中X为苯甲基或芳香或杂芳环。
• PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF
  申请人：Samjin Pharmaceutical Co., Ltd.

  公开号：EP3412670A1

  公开（公告）日：2018-12-12

  The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.

  本发明提供了一种新型吡啶衍生物、其药学上可接受的盐、制备方法以及含有其作为活性成分的药物组合物。根据本发明的吡啶衍生物可抑制 Raf 激酶（B-Raf、Raf-1 或 B-RafV600E）和参与血管生成的血管内皮生长因子受体（VEGFR2），因此可用于预防或治疗由 RAS 突变诱发的黑色素瘤、结直肠癌、前列腺癌、甲状腺癌、肺癌、胰腺癌、卵巢癌等。
• Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof
  申请人：SAMJIN PHARMACEUTICAL CO., LTD.

  公开号：US10844062B2

  公开（公告）日：2020-11-24

  The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.

  本发明提供了一种新型吡啶衍生物、其药学上可接受的盐、制备方法以及含有其作为活性成分的药物组合物。 根据本发明的吡啶衍生物可抑制 Raf 激酶（B-Raf、Raf-1 或 B-RafV600E）和参与血管生成的血管内皮生长因子受体（VEGFR2），因此可用于预防或治疗由 RAS 突变诱发的黑色素瘤、结直肠癌、前列腺癌、甲状腺癌、肺癌、胰腺癌、卵巢癌等。
• AMINO ACID DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
  申请人：Neuromed Pharmaceuticals Ltd.

  公开号：EP2155183A1

  公开（公告）日：2010-02-24
• Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof
  申请人：SAMJIN PHARMACEUTICAL CO., LTD.

  公开号：US20190300531A1

  公开（公告）日：2019-10-03

  The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.